Efficacy of INK128, an mTORC1/mTORC2 kinase inhibitor, in breast cancer models driven by HER2-PI3K-AKT-mTOR pathway.

C. Rommel,B. Leyland-Jones,N. Dey,Hui Wu,Yi Liu,P. De,Yuliang Sun
DOI: https://doi.org/10.1200/JCO.2012.30.15_SUPPL.626
2012-05-20
Abstract:626 Background: Downstream of the PI3K-AKT pathway, the mTOR has been shown to be essential effector in promoting cell proliferation, survival, mRNA translation and tumor susceptibility. Aberrant activation of the PI3K-AKT-mTOR pathway occurs frequently in breast tumor (BT) and contributes to resistance to trastuzumab (T). Using a HER2 amplified BT model; we investigated the antitumor efficacy of the dual mTORC1/mTORC2 kinase inhibitor INK128 alone and in combination with T. Methods: The antiproliferative and HER2-mediated cellular signaling (pAKT, pP70S6K, pS6RP, p4EBP1 and p-ERK) effects of INK128 alone and in combination with T were evaluated in HER2 amplified T-sensitive (BT474), T-resistant (BT474HR), and HER2 amplified/PIK3CA mutated (HCC1954, UACC893) BT cell lines by MTT assay and Western blots. Athymic mice bearing BT474 and BT474HR xenograft tumors were treated with INK128 and T (alone and in combination). Results: (1)INK128 exhibited excellent in vitro cell killing activity in MTT assay with IC...
Biology,Medicine
What problem does this paper attempt to address?